Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Jyong Biotech Ltd

MENS ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$1.74

▼ -7.94%

Market Cap $132.29M · Vol 54.33K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$132.29M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

24.42

Momentum

Beta

N/A

vs Market

52W High

$63.00

97.00% below

52W Low

$1.44

31.25% above

Volume

54.33K

Avg 14.62K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

37.80%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Jyong Biotech Ltd (MENS) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MENS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-12.12%

-26.89%

-34.09%

-23.68%

YTD

-55.95%

-97.12%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-4,671,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-34.42% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	76.03M

Technical Indicators

50-Day SMA	$2.10
200-Day SMA	$2.21
RSI (14)	24.42
Beta	N/A
52-Week High	$63.00
52-Week Low	$1.44

Volume Today	54.33K
Avg Daily Volume (30D)	14.62K
Relative Volume	3.72x
Volatility (10D)	60.52
Volatility (30D)	70.43
Free Float	37.80%

Analyst Consensus

N/A

Current Price $1.74

Mean Target N/A

52W Low$1.44 52W High$63.00

Current

Target

$1.44 $63.00

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIN/A

ISINKYG831161065

CountryTaiwan

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.74% ONC BeOne Medicines AG -1.08% 068270.KS Celltrion, Inc. -1.67% MEDP Medpace Holdings, Inc. -1.29% CRL Charles River Laboratories International, Inc. -1.51%

Company Profile

Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.